Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market by Type (Allogeneic CAR T-Cells, Autologous CAR T-Cells), By Application (Hospital, Diagnostic Center, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market by Type (Allogeneic CAR T-Cells, Autologous CAR T-Cells), By Application (Hospital, Diagnostic Center, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 382052 4200 Medical Care 377 225 Pages 4.9 (50)
                                          

Market Overview:


The global CAR T-cell immunotherapy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, technological advancements in CAR T-cell therapy, and rising funding for CAR T-cell therapy research. However, the high cost of treatment and lack of reimbursement policies are restraining the growth of this market. The global CAR T-cell immunotherapy market can be segmented on the basis of type into allogeneic CAR T-cells and autologous CAR T-cells. The allogeneicCART cell segment is expected to grow at a higher CAGR than the autologousCART cell segment duringthe forecast period from 2018to 2030. Thisgrowth can be attributedtothe increasing numberof clinical trials being conducted for allogeneicCART cellsand their potential benefits overautologousCART cellsin terms of efficacyand safety profile.


Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Industry Outlook


Product Definition:


Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy is a therapy that uses genetically modified T cells to battle cancer. The cells are modified to express a chimeric antigen receptor (CAR), which is a protein designed to target a specific antigen on the surface of cancer cells. The CAR T-cells are then infused into the patient, where they can seek out and kill cancer cells. CAR T-cell immunotherapy is important because it can be used to treat many types of cancer, including difficult-to-treat cancers like lymphoma and leukemia. It is also highly personalized, as each patient's CAR T cells are specifically tailored to target their own tumor's antigen.


Allogeneic CAR T-Cells:


Allogeneic CAR T-cells, it's usage and growth factor in Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy market: The global allogeneic CAR T-cell, it's usage and growth factor in chimeric antigen receptor t cell immunotherapy market size was valued at USD 4.6 billion in 2018 and is expected to grow at a CAGR of XX% over the forecast period.


Autologous CAR T-Cells:


Autologous CAR T-cells are a type of cell therapy that is used to treat cancer. These cells are taken from the patient's own immune system and modified with drugs and genetic engineering to make them attack & kill cancer cells. The therapy has shown efficacy in patients with advanced melanoma, lymphomas, and myelomas as well as acute lymphoblastic leukemia (ALL).


Application Insights:


The others segment includes research settings and home care settings. In the recent years, there has been a rise in the adoption of chimeric antigen receptor T-cell immunotherapy for treatment of cancer as well as other diseases. The hospital segment dominated the global market with a share of over 60% in 2017 owing to an increase in patient admissions for various chronic diseases such as solid tumors and hematological malignancies.


In addition, increasing government support towards R&D pertaining to chimeric antigen receptor T-cell immunotherapy is expected to boost industry growth during the forecast period.


Regional Analysis:


North America dominated the global market in 2017. This is due to the presence of a large number of players, high adoption rate of novel therapies, and increasing incidence of cancer. Moreover, government funding for research & development activities and increasing focus on clinical trials are some other factors contributing to the growth in this region. For instance, according to data published by ClinicalTrials.gov in 2018 till date there are no less than 584 U.S.


Growth Factors:


  • Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the CAR T-cell immunotherapy market. According to a study by the American Cancer Society, an estimated 1,688,780 new cases of cancer will be diagnosed in the U.S. in 2017 and about 600,920 people will die from the disease. This number is expected to rise significantly in the coming years due to factors such as population growth and aging. This will create a large pool of patients who can be treated with CAR T-cell immunotherapy drugs and drive market growth during the forecast period.
  • Rising demand for personalized medicines: The increasing demand for personalized medicines is another major driver for this market. With advances in technology and growing awareness about their benefits among patients and healthcare professionals alike, there is a rising demand for therapies that are tailored specifically to individual patients’ needs rather than using a one-size-fits-all approach. CAR T-cell immunotherapy drugs fit this requirement perfectly as they are customized according to each patient’s tumor type and genetic profile, making them more effective than traditional treatments options like chemotherapy or radiation therapy which often have harsh side effects that can impact quality of life adversely..

Scope Of The Report

Report Attributes

Report Details

Report Title

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Research Report

By Type

Allogeneic CAR T-Cells, Autologous CAR T-Cells

By Application

Hospital, Diagnostic Center, Others

By Companies

Pfizer, Novartis, Bristol Myers Squibb, Legend Biotech, Sorrento Therapeutics, CARSGEN Therapeutics,Ltd, Juno Therapeutics, Kite Pharma, Atara Biotherapeutics, Carina Biotech, Guangzhou Xiangxue Pharmaceutical

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

225

Number of Tables & Figures

158

Customization Available

Yes, the report can be customized as per your need.


Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Report Segments:

The global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy market is segmented on the basis of:

Types

Allogeneic CAR T-Cells, Autologous CAR T-Cells

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Diagnostic Center, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Pfizer
  2. Novartis
  3. Bristol Myers Squibb
  4. Legend Biotech
  5. Sorrento Therapeutics
  6. CARSGEN Therapeutics,Ltd
  7. Juno Therapeutics
  8. Kite Pharma
  9. Atara Biotherapeutics
  10. Carina Biotech
  11. Guangzhou Xiangxue Pharmaceutical

Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Overview


Highlights of The Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Allogeneic CAR T-Cells
    2. Autologous CAR T-Cells
  1. By Application:

    1. Hospital
    2. Diagnostic Center
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Chimeric antigen receptor (CAR) T-cell immunotherapy is a type of cancer treatment that uses genetically modified T cells to attack and kill cancer cells. These modified T cells are made from the patient's own immune system, which has been altered so that it can recognize and attack specific types of cancer.

Some of the major companies in the chimeric antigen receptor (car) t-cell immunotherapy market are Pfizer, Novartis, Bristol Myers Squibb, Legend Biotech, Sorrento Therapeutics, CARSGEN Therapeutics,Ltd, Juno Therapeutics, Kite Pharma, Atara Biotherapeutics, Carina Biotech, Guangzhou Xiangxue Pharmaceutical.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Size & Forecast, 2020-2028       4.5.1 Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Size and Y-o-Y Growth       4.5.2 Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 Allogeneic CAR T-Cells
      5.2.2 Autologous CAR T-Cells
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Diagnostic Center
      6.2.3 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 Allogeneic CAR T-Cells
      9.6.2 Autologous CAR T-Cells
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Diagnostic Center
      9.10.3 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 Allogeneic CAR T-Cells
      10.6.2 Autologous CAR T-Cells
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Diagnostic Center
      10.10.3 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 Allogeneic CAR T-Cells
      11.6.2 Autologous CAR T-Cells
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Diagnostic Center
      11.10.3 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 Allogeneic CAR T-Cells
      12.6.2 Autologous CAR T-Cells
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Diagnostic Center
      12.10.3 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 Allogeneic CAR T-Cells
      13.6.2 Autologous CAR T-Cells
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Diagnostic Center
      13.10.3 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market: Competitive Dashboard
   14.2 Global Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Pfizer
      14.3.2 Novartis
      14.3.3 Bristol Myers Squibb
      14.3.4 Legend Biotech
      14.3.5 Sorrento Therapeutics
      14.3.6 CARSGEN Therapeutics,Ltd
      14.3.7 Juno Therapeutics
      14.3.8 Kite Pharma
      14.3.9 Atara Biotherapeutics
      14.3.10 Carina Biotech
      14.3.11 Guangzhou Xiangxue Pharmaceutical

Our Trusted Clients

Contact Us